• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Changes in sexual function of women with refractory interstitial cystitis/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution
【24h】

Changes in sexual function of women with refractory interstitial cystitis/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution

机译：透明质酸溶液膀胱内治疗后难治性间质性膀胱炎/膀胱疼痛综合征女性的性功能变化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Intravesical instillation with a hyaluronic acid (HA) solution is an effective treatment for interstitial cystitis/bladder pain syndrome (IC/BPS), but its impact on sexual functioning of patients is not known. Aim: The aim of this study was to evaluate the changes in sexual function of women with refractory IC/BPS who underwent a second-line intravesical HA therapy. Methods: A total of 103 women diagnosed with refractory IC/BPS were enrolled in this prospective, multicenter study. Sexual function was evaluated using the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-9). Bladder-related symptoms and bother were assessed by the Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ICPI), and a pain visual analog scale (VAS), respectively. Data were analyzed with univariate methods or multivariate logistic regression analysis accordingly. Main Outcomes Measures: Changes in PISQ-9, ICSI, ICPI, and pain VAS scores after treatment were assessed. Results: Mean age and duration of symptoms was 43.6±11.8 and 5.1±5.0 years, respectively. ICSI, ICPI, and pain VAS scores were significantly (P<0.001) improved after 1 month and 6 months of treatment. Of the 87 (84.5%) sexually active women evaluated, PISQ-9 total scores improved significantly (P<0.001) from the baseline (mean 18.9±6.4), after 1 month (20.4±5.8), and 6-months (21.5±5.6) of treatment. Significantly improved PISQ-9 items included "dyspareunia" (P<0.001) and "negative reactions" (P=0.015) during sexual intercourse, and "intensity" (P<0.001) of sexual orgasms. After a logistic regression analysis, we found that a baseline PISQ-9 score was negatively correlated with the duration of IC/BPS symptoms (P=0.022). Meanwhile, the changes in PISQ-9 scores were positively correlated with the reduction in ICSI scores after treatment (P=0.045). Conclusions: Intravesical HA is an effective treatment for refractory IC/BPS. A longer duration of IC/BPS symptoms may be a predictor of poor sexual function. However, intravesical HA may improve sexual function along with the reduction of IC/BPS symptoms.
机译：简介：透明质酸（HA）溶液膀胱内滴注是一种治疗间质性膀胱炎/膀胱疼痛综合征（IC / BPS）的有效方法，但其对患者性功能的影响尚不清楚。目的：本研究旨在评估接受二线膀胱内HA治疗的难治性IC / BPS妇女的性功能变化。方法：该前瞻性，多中心研究共纳入103名被诊断为难治性IC / BPS的女性。使用盆腔器官脱垂/尿失禁性功能问卷（PISQ-9）的简短形式评估性功能。膀胱相关症状和烦恼分别通过间质性膀胱炎症状指数（ICSI）和间质性膀胱炎问题指数（ICPI）以及疼痛视觉模拟量表（VAS）进行评估。相应地使用单变量方法或多元逻辑回归分析来分析数据。主要结果指标：评估治疗后PISQ-9，ICSI，ICCPI和疼痛VAS评分的变化。结果：平均年龄和症状持续时间分别为43.6±11.8和5.1±5.0岁。治疗1个月和6个月后，ICSI，ICCPI和疼痛VAS评分显着改善（P <0.001）。在评估的87名（84.5％）有性活跃的妇女中，PISQ-9总分，分别在1个月（20.4±5.8）和6个月（21.5±2）时，较基线水平（平均18.9±6.4）有明显改善（P <0.001）。 5.6）治疗。 PISQ-9的显着改善包括性交过程中的“性交困难”（P <0.001）和“阴性反应”（P = 0.015），以及性高潮的“强度”（P <0.001）。经过逻辑回归分析后，我们发现基线PISQ-9得分与IC / BPS症状的持续时间负相关（P = 0.022）。同时，治疗后PISQ-9评分的变化与ICSI评分的降低呈正相关（P = 0.045）。结论：膀胱内HA是治疗难治性IC / BPS的有效方法。 IC / BPS症状持续时间较长可能预示着性功能不良。但是，膀胱内HA可以改善性功能，并减少IC / BPS症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号